Oct 22, 2020 / 12:30PM GMT
Operator
Good morning, and welcome to today's call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for one week from today.
I'll turn over the call to Jennifer Williams, Investor Relations for Omeros.
Jennifer Williams -
Good morning, and thank you for joining today to discuss the final data from our pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, which we'll refer to today as TA-TMA. The slide presentation accompanying this morning's call are available on our website at www.omeros.com.
I'd like to remind you that some of the statements that will be made on today's call will be forward-looking. These forward-looking statements include, without limitation, statements regarding the efficacy, safety and intended utilization of our investigational product, planned regulatory submissions and
Omeros Corporation - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot